Metizol (Thiamazole)

Thiamazole blocks the enzyme thyroid peroxidase, preventing the iodination of tyrosine residues in thyroglobulin and the coupling reactions needed to form T4 and T3 hormones. This inhibition reduces the amount of active thyroid hormone released into the bloodstream.

The dosage of Metizol is individualized by the prescribing clinician based on the severity of the thyroid disorder, patient age, weight, and response to therapy. Only a qualified healthcare professional should determine the appropriate dose.

Thiamazole crosses the placenta and may affect fetal thyroid function. It should be used in pregnancy only when the potential benefit justifies the risk. During breastfeeding, thiamazole is excreted in milk; a risk‑benefit assessment is required before continuation.

To request Metizol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metizol (thiamazole) is often preferred over propylthiouracil because of its longer half‑life, once‑ or twice‑daily dosing, and lower risk of severe liver toxicity. Both drugs inhibit thyroid hormone synthesis, but thiamazole generally offers a more convenient dosing schedule.

Metizol tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Do not store in a bathroom or near heat sources, and keep out of reach of children.

Metizol is taken orally, usually with a glass of water. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal upset. The exact schedule (once or twice daily) is set by the prescriber.

The most serious adverse effects include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe liver injury. Patients should report fever, sore throat, jaundice, or unusual bruising promptly, as these may signal serious complications.

Metizol is contraindicated in individuals with known hypersensitivity to thiamazole or any of its excipients, in patients with severe liver disease, and in those who have experienced agranulocytosis from prior antithyroid therapy. Caution is also advised for pregnant women and patients with renal impairment.